Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Mason J Webb"'
Autor:
Mason J Webb, William G Breen, Nadia N Laack, Konstantinos Leventakos, Jian L Campian, Ugur Sener
Publikováno v:
CNS Oncology, Vol 12, Iss 3 (2023)
Leptomeningeal disease (LMD) remains a challenging condition with a dismal prognosis. In this case study, we report partial response of LMD in a patient with metastatic large cell neuroendocrine carcinoma following treatment with proton craniospinal
Externí odkaz:
https://doaj.org/article/d3b7047a102c45deb04e6372c3d0e4c3
Autor:
Mason J. Webb, Timothy Kottke, Benjamin L. Kendall, Jack Swanson, Chisom Uzendu, Jason Tonne, Jill Thompson, Muriel Metko, Madelyn Moore, Mitesh Borad, Lewis Roberts, Rosa M. Diaz, Michael Olin, Antonella Borgatti, Richard Vile
Publikováno v:
Molecular Therapy - Oncolytics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cca396acf6f80f4a1d078c8851a58b80
https://doi.org/10.1016/j.omto.2023.05.006
https://doi.org/10.1016/j.omto.2023.05.006
Publikováno v:
Pharmaceuticals. 16:793
Despite decades of research and numerous clinical trials, the prognosis of patients diagnosed with glioblastoma (GBM) remains dire with median observed survival at 8 months. There is a critical need for novel treatments for GBM, which is the most com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6af94ddb2c7f39ddbee2a35ece30413c
https://doi.org/10.3390/ph16060793
https://doi.org/10.3390/ph16060793
Publikováno v:
Pharmaceutics. 15:1134
Glioblastoma (GBM) is the most common malignant primary brain tumor and confers a dismal prognosis. With only two FDA-approved therapeutics showing modest survival gains since 2005, there is a great need for the development of other disease-targeted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e06a3f5a0f79820370fc99886e558a1
https://doi.org/10.3390/pharmaceutics15041134
https://doi.org/10.3390/pharmaceutics15041134
Publikováno v:
Mayo Clinic proceedings. 97(9)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0720991706adb002a0a0f0ff52f48aad
https://pubmed.ncbi.nlm.nih.gov/36058585
https://pubmed.ncbi.nlm.nih.gov/36058585
Publikováno v:
Mayo Clinic proceedings. 96(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3af341256a0929359d0c268301ea7051
https://pubmed.ncbi.nlm.nih.gov/33714598
https://pubmed.ncbi.nlm.nih.gov/33714598
Autor:
Mason J. Webb, Thanich Sangsuwannukul, Jacob van Vloten, Laura Evgin, Benjamin Kendall, Jason Tonne, Jill Thompson, Muriel Metko, Madelyn Moore, Maria P. Chiriboga Yerovi, Michael Olin, Antonella Borgatti, Mark McNiven, Satdarshan P. S. Monga, Mitesh J. Borad, Alan Melcher, Lewis R. Roberts, Richard Vile
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Although patients benefit from immune checkpoint inhibition (ICI) therapy in a broad variety of tumors, resistance may arise from immune suppressive tumor microenvironments (TME), which is particularly true of hepatocellular carcinoma (HCC).
Externí odkaz:
https://doaj.org/article/3cf0fc38fa494b069051f0ff5e7872c6
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Vol 7, Iss 2, Pp 97-110 (2024)
Abstract: Glioblastoma (GBM) is the most prevalent malignant tumor of the central nervous system. The prognosis of GBM is grim, with a median overall survival of 14.6 months and only 6.9% of patients surviving 5 years after the initial diagnosis. Des
Externí odkaz:
https://doaj.org/article/3cfd5e6154b74787b96b4d64d9a84ea8